Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat. After operating in the challenging biotech sector for nearly three decades, we've evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. Cancer is our cause. Make it yours, too. Please see our Community Guidelines: bit.ly/4iBzJU0 For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
1 signal in the last 90 days.
The order this company entered each market — oldest to newest
Director
Sign up to see the full signal feed
How Exelixis's international expansion compares to its competitors
ExelixisYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 ExelixisYou | 1 | 1 | -100% | 1 | 31 |
Associate GPO Strategic Partner Marketing and Operations Director
View postingAlameda, CA · last wk.
Associate Director, Stability Management
View postingAlameda, CA · 2w ago
PSC Operations Management Director
View postingAlameda, CA · 2w ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
ADG126 shows promising results in treating MSS CRC when combined with anti-PD-1 therapy. Higher doses and frequency demonstrate clinical benefits, with expanded trials planned for 2024.
Exelixis to release Q3 results after analyst downgrade. Biotech firm must impress with strong results following mixed previous quarter data.
FirstBio Therapeutics established a Scientific Advisory Board with former global pharma R&D leaders to advance FB849 immunotherapy and neurodegenerative disease pipeline development.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Exelixis's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
